Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Korábbi kezelés

• 2. Treatment with other anti-cancer therapies and cannot be stopped currently
• 9. Serious Risks or Serious Adverse Events of the drug product
• 10. The prohibition of drug products

Más betegség

• 5. The patients with other serious intercurrent illness or infectious diseases
• 6. Have more than one different kind of cancer at the same time
• 7. Serious Allergy to Drugs

Egyéb

• 1. Pneumonectomy
• 3. Pregnancy
• 4. Breast-feeding
• 8. Serious Bleed Tendency
• 11. Have no therapeutic effects
• 12. Follow up to the most current label

• 1. Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC) as follows:
• Took ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily more than 90 days
• Had no further NSCLC metastatic or growth in more than previous 90 days
• 2. Suitable for enough blood-drawing
• 3. Sequential Assignment
• 4. Measurable disease
• 5. Adequate organ functions
• 6. Adequate performance status
• 7. Age 24-64 years old
• 8. Sign an informed consent form
• 9. Receive blood-drawing

A regiszterben nem jelölt feltételek

• Select 600 patients with Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC) as follows:
  • Took ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily more than 90 days
  • Had no further NSCLC metastatic or growth in more than previous 90 days
• Dosage Duration at least 90 days
• The usual approach group - Recruit 300 Sequential Assignment group separated NSCLC patients currently used the Chemotherapy NDC...01 on ALECENSA capsule 600 mg orally twice daily, diagnosed metastatic ALK-positive NSCLC, like as the usual approach group.
• The study approach group - Recruit 300 Sequential Assignment group separated NSCLC patients currently used the Chemotherapy NDC...86 on ALECENSA capsule 600 mg orally twice daily, diagnosed metastatic ALK-positive NSCLC, like as the study approach group.